CAMPBELL, Calif.--(BUSINESS WIRE)--Imperative Care Launches Zoom 4S Catheter to Further Advance Company's Zoom Stroke System for Ischemic Stroke Treatment. ...

GERMANTOWN, Md., Jan. 28, 2026 (GLOBE NEWSWIRE) -- Senseonics Holdings, Inc. (NASDAQ: SENS), a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, today announced that management will participate in the BTIG 13th Annual MedTech, Digital Health, Life Science & Diagnostic Tools Conference on Wednesday, February 11, 2026 in Snowbird, Utah. To request a meeting with Senseonics, investors should co ...

Core Viewpoint - A class action lawsuit has been filed against Integer Holdings Corporation and certain senior executives for securities fraud following a significant drop in stock price due to alleged violations of federal securities laws [1][3]. Company Overview - Integer Holdings Corporation specializes in designing and manufacturing cardiac rhythm management and cardiovascular products, including electrophysiology devices that diagnose and treat arrhythmias [4]. Allegations of Securities Fraud - The lawsuit claims that Integer misrepresented the demand and revenue for its electrophysiology products, which had reportedly fallen sharply, contradicting the company's public statements about sales growth and market position [4][5]. Stock Price Decline - On October 23, 2025, Integer announced a reduction in its 2025 sales guidance to between $1.840 billion and $1.854 billion, down from a previous range of $1.850 billion to $1.876 billion, which was below analysts' expectations. The company also projected poor net sales growth of -2% to 2% and organic sales growth of 0% to 4% for 2026. This announcement led to a stock price drop of $35.22 per share, or over 32%, from $109.11 on October 22, 2025, to $73.89 on October 23, 2025 [6].

Core Insights - Outset Medical, Inc. (OM) has received 510(k) clearance for its next-generation Tablo hemodialysis system, marking a significant regulatory achievement and establishing Tablo as the first dialysis system compliant with the FDA's latest cybersecurity standards [1][4] - The upgraded Tablo platform features enhancements in cybersecurity, reliability, and usability, targeting hospitals, health systems, and home dialysis providers [2][5] Stock Performance - Following the announcement of the clearance, OM's shares increased by 14.3% in the trading session, although the stock has seen a decline of 68.6% over the past six months compared to a 19.8% decline in the industry [3] Long-term Implications - The clearance is expected to facilitate easier adoption of Tablo by hospitals and health systems that prioritize security and compliance, potentially leading to increased revenue visibility and a stronger market position for OM [4] - OM's current market capitalization stands at $90.2 million [4] Product Enhancements - The redesigned Tablo platform incorporates cybersecurity across its hardware, software, and cloud components, aligning with modern hospital IT requirements [5][6] - The new Tablo system is set to begin shipping in Q2 2026, with existing customers eligible for upgrades [6][8] Clinical Outcomes - Recent research indicates that Tablo has been used in over 1 million hemodialysis treatments across approximately 750 facilities, demonstrating significant clinical outcomes, including a 94% reduction in serious cardiac or respiratory events [10]

Core Insights - Johnson & Johnson (JNJ) reported strong fourth-quarter 2025 results, with total revenues increasing by 9.1% to $24.56 billion and adjusted EPS rising by 20.6% year over year to $2.46 [1][10] - The company expects sales in 2026 to be between $100 billion and $101 billion, with adjusted EPS projected in the range of $11.43 to $11.63 [3][10] Innovative Medicines Segment - Despite the loss of exclusivity for Stelara, sales in the Innovative Medicines unit grew by 10.0% year over year to $15.76 billion in Q4 2025 [2][10] - The segment achieved over $60 billion in full-year sales for the first time in 2025, with 13 brands experiencing double-digit growth [6] - J&J anticipates continued growth in the Innovative Medicine segment in 2026, driven by key products and new launches, expecting a growth rate of 5% to 7% from 2025 to 2030 [7][10] MedTech Segment - The MedTech segment saw sales rise by 7.5% to $8.8 billion in Q4 2025, supported by strong performance in Cardiovascular, Surgery, and Vision [2][10] - J&J expects improved growth in the MedTech business in 2026, driven by new product launches across its portfolios [15][10] - The potential separation of the Orthopaedics franchise into a standalone company is expected to enhance growth and margins for the MedTech unit [14] Research and Development - J&J invested over $32 billion in R&D and M&A in 2025, including acquisitions that expanded its product portfolio [8] - The company achieved significant clinical and regulatory milestones, gaining approvals for new products that are expected to drive growth [9] Legal and Market Challenges - J&J faces challenges from the loss of patent exclusivity for Stelara, which accounted for approximately 18% of the Innovative Medicine unit's sales in 2024 [17] - The company is also dealing with the impact of the Medicare Part D redesign and ongoing legal battles related to its talc-based products [19][20] Stock Performance and Valuation - JNJ's stock has outperformed the industry, rising 48.5% over the past year compared to a 20.0% increase in the industry [23] - The stock is currently trading at a price/earnings ratio of 19.36, slightly above the industry average [25] - Earnings estimates for 2026 have increased, reflecting J&J's optimistic financial outlook [27] Overall Outlook - J&J's diversified business model, strong cash flows, and consistent dividend increases position the company well for future growth despite facing headwinds [30][31]

Core Thesis - Boston Scientific Corporation (BSX) presents a tactical investment opportunity following its $14.5 billion acquisition of Penumbra, which led to a temporary 4% decline in stock price [2][5] Financial Metrics - As of January 27th, BSX's share price was $93.61, with trailing and forward P/E ratios of 50.06 and 26.95 respectively [1] Market Reaction - The acquisition caused a short-term dip in stock price, prompting traders to sell April $80 puts, currently out-of-the-money by approximately 11%, collecting $1.10 per share in premium, totaling $440,000 from 4,000 contracts [2][3] Institutional Positioning - A surge in trading volume exceeding 8,700 contracts indicates strong institutional conviction, capitalizing on the market's overreaction to earnings dilution of $0.06–$0.08 per share and the $11 billion financing for the acquisition [3] Options Market Dynamics - Elevated implied volatility surrounding the acquisition and upcoming February earnings inflates option premiums, creating a favorable environment for put sellers who expect volatility to decrease post-acquisition [4] Analyst Ratings - Analysts from Needham and Morgan Stanley maintain Buy ratings with price targets between $121 and $127, reflecting confidence in BSX's long-term fundamentals [5] Growth Projections - BSX has reaffirmed its double-digit EPS growth targets for 2026–2028, positioning itself to dominate high-growth neurovascular and thrombectomy markets following the Penumbra acquisition [5] Risk Considerations - The primary risk involves acquisition integration challenges, including regulatory hurdles and market perception of overpayment, although a breakeven point at $78.90 provides a cushion for investors [5]

Core Insights - ENvue Medical has signed a distribution agreement with U-Deliver to expand access to its ENFit Syringes across non-acute care channels nationwide [1][2] - The partnership aims to enhance ENvue's presence in the non-acute enteral care market, focusing on providing reliable and safe solutions for feeding and medication delivery [2] Company Overview - ENvue Medical, Inc. specializes in intelligent, non-invasive solutions for enteral care in clinical and home care settings, headquartered in Tyler, Texas [4] - The company has a research and development presence in Tel-Aviv and Nesher, Israel, and operates two distinct technology platforms [4] Product Details - ENvue's ENFit Syringes are available in sizes of 2.5 mL, 5 mL, 10 mL, and 60 mL, and do not require a prescription [2] - The syringes meet ISO 80369-3 global standards and can be reused for up to seven days or 20 uses, ensuring safe enteral delivery [2] Partner Overview - U-Deliver is a U.S.-based supplier focused on enteral feeding supplies for home and long-term care settings, serving non-acute care customers through online and distribution channels [3]

Company Overview - ENvue Medical Inc., formerly known as NanoVibronix Inc., specializes in intelligent, non-invasive solutions for enteral care in clinical and home care settings [2] - The rebranding aims to better reflect the company's strategic direction and focus on the ENvue feeding-tube placement system [2] Recent Developments - ENvue Medical has signed a distribution agreement with U-Deliver to distribute its over-the-counter reusable ENFit Syringes nationwide through non-acute care channels [1] - The ENFit Syringes are designed to meet clinical needs for both feeding and medication delivery [1] Product Details - The ENFit Syringes are available in sizes of 2.5 mL, 5 mL, 10 mL, and 60 mL, and can be purchased without a prescription [4] - These syringes can be reused for up to seven days or 20 uses, ensuring safe and consistent enteral delivery in various care environments [4] Market Presence - The partnership with U-Deliver is seen as a significant step in scaling the ENFit syringe line and enhancing ENvue's presence in the non-acute enteral care market [3] - ENvue Medical's stock is currently trading at $1.26, reflecting a 20.124% increase during premarket trading [5]

Core Insights - Boston Scientific (BSX) is expected to report its fourth-quarter 2025 results on February 4, with earnings per share (EPS) anticipated at 78 cents, reflecting an 11.4% growth year-over-year, and revenues projected at $5.27 billion, indicating a 15.4% increase from the previous year [1][2]. Group 1: Financial Performance - The Zacks Consensus Estimate for BSX's revenues is set at $5.27 billion, which represents a 15.4% increase compared to the same quarter last year [2]. - The consensus for earnings is pegged at 78 cents per share, indicating an 11.4% growth from the year-ago quarter [2]. - BSX has consistently beaten earnings estimates in the past four quarters, with an average surprise of 7.36% [1]. Group 2: Business Segment Performance - The MedSurg division is expected to maintain strong sales momentum, with revenues estimated at $1.80 billion, suggesting an 11.4% year-over-year increase, driven by the Endoscopy and Urology businesses [4][7]. - The Cardiovascular segment is projected to see a 17.5% increase in revenues to $3.46 billion, supported by the uptake of WATCHMAN and FARAPULSE products [9][14]. - The Neuromodulation segment is anticipated to grow, bolstered by the Pain franchise and the acquisition of Nalu Medical, which expands BSX's portfolio in peripheral nerve pain [6]. Group 3: Market Developments - The Endoscopy business within MedSurg is benefiting from the Axios platform and the adoption of innovative technologies like OverStitch and Mantis clip [4]. - The Cardiovascular business is expected to perform well due to strong growth in coronary therapies, particularly from the AGENT Drug-Coated Balloon and the WATCHMAN FLX Pro device's launch in China [10][11]. - The Peripheral Interventions unit is likely to continue its growth trend, despite challenges in the Chinese market, with strong performance in Interventional Oncology & Embolization [13].

Core Insights - Vivos Inc. has been granted U.S. Patent No. 12,521,452 B2 for its innovative cancer treatment technology, specifically a radioactive thermogel suspension that enhances its Precision Radionuclide TherapyTM platform [1][2] Patent and Technology - The patent protects a novel thermosensitive PLGA-g-PEG hydrogel combined with yttrium-90 particles, allowing for precise, localized radiation delivery to solid tumors while minimizing damage to healthy tissue [2] - The gel remains injectable at room temperature and solidifies at body temperature, ensuring effective immobilization of the radiation source [2] Intellectual Property Developments - Vivos has received approval for its PRECISIONGEL™ trademark in the U.S. and New Zealand, and has filed a new patent application to further protect its hydrogel technology [3] - The new application covers the hydrogel's use as a carrier for various therapeutic agents, reinforcing the company's position in advanced hydrogel-based delivery systems [3] Strategic Vision - The CEO of Vivos Inc. emphasized that these milestones significantly enhance the company's intellectual property portfolio, supporting clinical progress and potential strategic partnerships [4] - The focus on building a strong IP position is aimed at driving shareholder value and enabling global commercial expansion [4] Company Overview - Vivos Inc. is a clinical-stage medical device company developing RadioGel® for human oncology and IsoPet® for veterinary applications, with IsoPet® already available in certified clinics across the nation [5]